Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 885-891

  Van Wart, Scott A ^a   Ambrose, Paul G ^a   Rubino, Christopher M ^a   Khariton, Tatiana ^b   Riccobene, Todd A ^b   Friedland, H David ^c   Critchley, Ian A ^c   Bhavnani, Sujata M ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE FOSAMIL;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ACUTE DISEASE; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; COMPARTMENT MODEL; FEMALE; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MILD RENAL IMPAIRMENT; MINIMUM INHIBITORY CONCENTRATION; MODERATE RENAL IMPAIRMENT; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEVERE RENAL IMPAIRMENT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VERY ELDERLY;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONTE CARLO METHOD; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84893444731     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01680-13     Document Type: Article

References (24)

1. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
2. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. 2013. Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa. I. Cephalosporins and aztreonam. Clin. Infect. Dis. 56:1301-1309. http://dx.doi.org/10.1093/cid/cit017.
3. Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E. 2009. Application of patient populationderived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn. Microbiol. Infect. Dis. 63:155-159. http://dx.doi.org/10.1016/j.diagmicrobio.2008.10.011.
4. Bhavnani SM, Rubino CM, Forrest A, Okusanya OO, Craig WA, Moeck G, Lehoux D, Parr TR, Jr, Ambrose PG. 2008. Pharmacokineticpharmacodynamic target attainment as decision support for oritavancin susceptibility breakpoints for Staphylococcus aureus, abstr A-994. Abstr. 48th Intersci Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
5. Laudano JB. 2011. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J. Antimicrob. Chemother. 66(Suppl 3):11-18. http://dx.doi.org/ 10.1093/jac/dkr095.
6. Forest Pharmaceuticals, Inc. 2013. Teflaro package insert. Forest Pharmaceuticals, Inc., St Louis, MO.
7. AstraZeneca AB. 2012. Zinforo, summary of product characteristics. AstraZeneca AB, Sodertalje, Sweden.
8. Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Riccobene TA, Ambrose PG. 2013. Population pharmacokinetics of ceftaroline in patients with complicated skin and skin structure infections or community-acquired pneumonia. J. Clin. Pharmacol. 53:1155-1167.
9. Andes D, Craig WA. 2006. Pharmacodyamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50: 1376-1383. http://dx.doi.org/10.1128/AAC.50.4.1376-1383.2006.
10. Beal SL, Sheiner LB, Boeckmann AJ. 2006. NONMEM users guides. ICON Development Solutions, Ellicott City, MD.
11. SAS Institute Inc. 2010. SAS OnlineDoc9.2. SAS Institute Inc., Cary, NC.
12. Talbot GH, Thye D, Das A, Ge Yigong. 2007. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51:3612-3616. http://dx.doi.org/10. 1128/AAC.00590-07.
13. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 1 investigators. 2010. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):41-51. http://dx.doi.org/10.1093/jac/dkq254.
14. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, CANVAS 2 investigators. 2010. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl 4):53-65. http://dx.doi.org/10.1093/jac/dkq255.
15. File TM, Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchely IA, Thye DA. 2011. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):19-32. http://dx.doi.org/10.1093/jac/dkr096.
16. Low DE, File TM, Jr, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA. 2011. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 66(Suppl 3):33-44. http://dx.doi.org/10.1093/jac/dkr097.
17. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86. http://dx.doi.org/10.1086/ 510079.
18. Jones RN, Mendes RE, Sader HS. 2010. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J. Antimicrob. Chemother. 65(Suppl 4):17-31. http://dx.doi.org/10.1093/jac/dkq252.
19. Jones RN, Farrell DJ, Mendes RE, Sader HS. 2011. Comparative ceftaroline activity tested against pathogens associated with communityacquired pneumonia: results from an international surveillance study. J. Antimicrob. Chemother. 66(Suppl 3):69-80. http://dx.doi.org/10.1093/jac/dkr101.
20. Bhavnani SM, Hammel JP, Van Wart SA, Rubino CR, Reynolds DK, Forrest A, Drusano DL, Khariton T, Riccobene TA, Ambrose PG. 2011. Pharmacokinetic- pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with complicated skin and skin structure infections, abstr A2-552. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.
21. Bhavnani SM, Hammel JP, Van Wart SA, Rubino CR, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG. 2013. Pharmacokinetic- pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia. Antimicrob. Agents Chemother. 57:6348-6350. http://dx.doi.org/10.1128/AAC.01748-13.
22. Forest Pharmaceuticals, Inc. 2012. Teflaro package insert. Forest Pharmaceuticals, Inc., St Louis, MO.
23. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd information supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
24. European Committee on Antimicrobial Susceptibility Testing. 2013. Clinical breakpoint table v. 3.1 9 (valid from 02-11). http://www.eucast.org/ fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Break point-table-v-3.1.pdf. Accessed 22 February 2013.